scholarly journals SF007/#206 A systematic approach for achieving optimal cytoreduction of locally advanced endometrial cancer by a robotic approach

2021 ◽  
Author(s):  
G Feuer ◽  
I Mousavi ◽  
N Lakhi
Keyword(s):  
Endometrial Cancer ◽  
Systematic Approach ◽  
Locally Advanced ◽  
Optimal Cytoreduction ◽  
Robotic Approach

Robotic approach to locally advanced rectal cancer: video vignette

2021 ◽  
Author(s):  
Ibrahim Amer ◽  
Mahwish Khawar ◽  
Hafiz Bilal Zafar ◽  
Mahmood Al Dhaheri ◽  
Mohammad Abu Nada ◽  
...  
Keyword(s):  
Rectal Cancer ◽  
Locally Advanced ◽  
Advanced Rectal Cancer ◽  
Locally Advanced Rectal Cancer ◽  
Robotic Approach ◽  
Video Vignette

Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1–Positive Endometrial Cancer: Results From the KEYNOTE-028 Study

2017 ◽  
Vol 35 (22) ◽  
pp. 2535-2541 ◽  
Author(s):  
Patrick A. Ott ◽  
Yung-Jue Bang ◽  
Dominique Berton-Rigaud ◽  
Elena Elez ◽  
Michael J. Pishvaian ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Antitumor Activity ◽  
Partial Response ◽  
Objective Response ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Programmed Death Ligand 1 ◽  
Programmed Death ◽  
Duration Of Response ◽  
Heavily Pretreated

Purpose The multicohort phase Ib KEYNOTE-028 (NCT02054806) study was designed to evaluate the safety and efficacy of pembrolizumab, an anti–programmed death 1 monoclonal antibody, in patients with programmed death ligand 1 (PD-L1) –positive advanced solid tumors. The results from the advanced endometrial cancer cohort are reported. Patients and Methods Female patients with locally advanced or metastatic PD-L1–positive endometrial cancer who had experienced progression after standard therapy were eligible. Patients received pembrolizumab 10 mg/kg every 2 weeks for up to 24 months or until progression or unacceptable toxicity. Primary efficacy end point was objective response rate by RECIST (version 1.1). Secondary end points included safety, duration of response (DOR), progression-free survival, and overall survival. The data cutoff was February 17, 2016. Results Of 75 patients screened, 36 (48.0%) had PD-L1–positive tumors, and 24 (32.0%) were enrolled. Fifteen (62.5%) of these 24 patients had received at least two previous lines of therapy for advanced disease. Three patients (13.0%) achieved confirmed partial response (95% CI, 2.8% to 33.6%); the median DOR was not reached. Two patients were still receiving treatment and exhibiting continued response at time of data cutoff. Three additional patients (13.0%) achieved stable disease, with a median duration of 24.6 weeks. One patient who achieved partial response had a polymerase E mutation. Thirteen patients (54.2%) experienced treatment-related adverse events (AEs), with fatigue (20.8%), pruritus (16.7%), pyrexia (12.5%), and decreased appetite (12.5%) occurring in ≥ 10% of patients. Grade 3 treatment-related AEs were reported in four patients. No patient experienced a grade 4 AE, and no patient discontinued treatment because of an AE. Conclusion Pembrolizumab demonstrated a favorable safety profile and durable antitumor activity in a subgroup of patients with heavily pretreated advanced PD-L1–positive endometrial cancer.

The influence of cytoreductive surgery on survival and morbidity in stage IVB endometrial cancer

2002 ◽  
Vol 12 (5) ◽  
pp. 448-453 ◽  
Author(s):  
A. Ayhan ◽  
C. Taskiran ◽  
C. Celik ◽  
K. Yuce ◽  
T. Kucukali
Keyword(s):  
Endometrial Cancer ◽  
Cancer Patients ◽  
Median Survival ◽  
Adjuvant Treatment ◽  
Cytoreductive Surgery ◽  
Univariate Analysis ◽  
Optimal Cytoreduction ◽  
Surgical Morbidity ◽  
Maximal Diameter ◽  
Stage Ivb

The purpose of this study was to detect possible survival advantages of surgical cytoreduction and different adjuvant treatment regimens for stage IVB endometrial cancer patients, and also to evaluate the prognostic importance of surgico-pathological risk factors and surgical morbidity rates.Thirty-seven FIGO stage IVB endometrial cancer patients treated at the Hacettepe University Hospital between 1977 and 1998 were included in this study. Clinical data were obtained from the private oncology files and all specimens were re-evaluated by the co-author pathologist. Optimal cytoreduction was defined as a surgical procedure leaving the patient with ≤1 cm residual disease in maximal diameter. All patients were subjected to initial cytoreductive surgery, but it had been achieved for 22 (60%) patients. Fourteen (38%) patients received both radiotherapy and chemotherapy, 10 (27%) patients received only radiotherapy and the other 10 (27%) patients received only chemotherapy. Three patients refused any type of adjuvant therapy.The median survival of the suboptimally cytoreduced patients was 10 months, while the median survival in the optimal group was 25 months (P = 0.001). In optimal cytoreduction group, the median survival for 12 (55%) patients without visible tumor was 48 months compared to 13 months in 10 (45%) patients with visible tumor. As an adjuvant treatment, concomitant cisplatin and radiotherapy revealed 54 months median survival compared to 15 and 13 months in patients treated with only radiotherapy and only chemotherapy, respectively. By univariate analysis, extra-abdominal metastases, suboptimal cytoreduction, visible tumoral mass after cytoreduction, pelvic-para-aortic lymphatic metastases, and cervical invasion were found to be significant predictors of poor survival. In multivariate analysis, optimal cytoreduction, concomitant cisplatin-radiotherapy treatment, and extra-abdominal metastases were significant. Morbidity was mild in six (16%), and severe in nine (24%) patients.We conclude that optimal cytoreduction achieved significant survival benefit for stage IVB endometrial cancer patients with a reasonable surgical morbidity rate. As an adjuvant treatment, concomitant cisplatin and radiotherapy was the best choice.

Impact of obesity on surgical and oncologic outcomes in patients with endometrial cancer treated with a robotic approach

2020 ◽  
Vol 47 (1) ◽  
pp. 128-136
Author(s):  
Eri Kawai ◽  
Louise Benoit ◽  
Judicael Hotton ◽  
Bastien Rance ◽  
Hélène Bonsang‐Kitzis ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Oncologic Outcomes ◽  
Robotic Approach

scholarly journals Regional Control and Dose-Response for Chemoradiotherapy in Locally-Advanced Endometrial Cancer

2019 ◽  
Vol 105 (1) ◽  
pp. S227
Author(s):  
U.K. Iheagwara ◽  
J.A. Vargo ◽  
M.M. Boisen ◽  
S.E. Taylor ◽  
J.L. Berger ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Dose Response ◽  
Locally Advanced ◽  
Regional Control

scholarly journals Neoadjuvant High-Dose-Rate Brachytherapy Followed By Extrafascial Hysterectomy for Locally Advanced Endometrial Cancer Clinically Extending to Cervix or Parametria

Brachytherapy ◽  
2015 ◽  
Vol 14 ◽  
pp. S18
Author(s):  
John A. Vargo ◽  
Michelle M. Boisen ◽  
John T. Comerci ◽  
Hayeon Kim ◽  
Christopher J. Houser ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Dose Rate ◽  
Locally Advanced ◽  
High Dose Rate ◽  
High Dose ◽  
High Dose Rate Brachytherapy

Robotic approach using simple and radical hysterectomy for endometrial cancer with long-term follow-up evaluation

2015 ◽  
Vol 12 (1) ◽  
pp. 109-113 ◽  
Author(s):  
Gianluca Raffaello Damiani ◽  
Daniela Turoli ◽  
Gennaro Cormio ◽  
Paolo Croce ◽  
Viviana Merola ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Radical Hysterectomy ◽  
Robotic Approach ◽  
Long Term Follow Up

What’s New in Gynaecological Oncology?

2011 ◽  
Vol 07 (03) ◽  
pp. 188
Author(s):  
Giovanni Di Vagno ◽  
Keyword(s):  
Endometrial Cancer ◽  
Lymph Node ◽  
High Risk ◽  
Preterm Delivery ◽  
Lymph Node Dissection ◽  
Ca 125 ◽  
Optimal Cytoreduction ◽  
Node Dissection ◽  
Aortic Lymph Node ◽  
Hpv Genotypes

Is para-aortic lymph node dissection beneficial in the treatment of endometrial cancer? Para-aortic lymph node dissection is associated with a survival benefit in women with intermediate or high-risk endometrial cancer: a retrospective cohort study of women with endometrial cancer reported that eight-year, disease-specific survival rates were significantly higher for women with intermediate or high-risk disease who underwent combined pelvic and para-aortic lymph node dissection compared with pelvic lymph node dissection alone; there was, however, no significant difference in women with low-risk disease. What is the best, cutting-edge management for clear cell and papillary serous cancers of the endometrium? There is increasing evidence of the efficacy of an integrated and modified approach for these special histotypes compared with standard treatment for endometrial cancer: platinum/taxane-based chemotherapy is effective in determining relapse/survival benefits of both early- and advanced-stage patients. Is it possible to predict optimal cytoreduction in ovarian cancer? A high preoperative serum CA-125 level is associated with a lower likelihood of optimal cytoreduction: a meta-analysis of 14 studies found that serum CA-125 ≥500 U/ml has sensitivity and specificity for optimal cytoreduction of 69 and 63 %, respectively. Can multiple conisation procedures increase the risk of preterm delivery? The risk of preterm delivery increases in women with cervical intraepithelial neoplasia who undergo more than one cervical conisation. A population-based retrospective study reported that, compared with women who have undergone one prior conisation, the risk of preterm delivery increases threefold in women with two prior conisations. How often do the human papillomavirus (HPV) genotypes 16 and 18 cause invasive cervical cancer? In recent decades, the rate at which the major HPV genotypes (contained within HPV vaccines) caused invasive cervical cancers remained stable. This observation is crucial, given the large amount of public money invested in prophylactic HPV vaccine campaigns.

Sign in / Sign up

Export Citation Format

Share Document